Press Releases - G1 Therapeutics, Inc.

Press Releases

Date	Title
11/23/22	G1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx Conference
11/22/22	G1 Therapeutics Announces Closing of Offering of Common Stock
11/17/22	G1 Therapeutics Announces Pricing of Offering of Common Stock
11/17/22	G1 Therapeutics Announces Proposed Public Offering of Common Stock
11/2/22	G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights
11/2/22	Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)
11/1/22	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/26/22	G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
10/19/22	G1 Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 2, 2022
10/10/22	G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)